Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 10Observational 1Expanded_access 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 32Multiple Myeloma 26Neoplasms 25Recurrence 23Melanoma 19Leukemia, Myeloid, Acute 16Breast Neoplasms 15Prostatic Neoplasms 12Pancreatic Neoplasms 11Glioblastoma 11Sarcoma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lung Neoplasms 9Ovarian Neoplasms 8Lymphoma 8Glioma 8Colorectal Neoplasms 8Small Cell Lung Carcinoma 7Lymphoma, Large B-Cell, Diffuse 7Carcinoma, Renal Cell 7Lymphoma, Non-Hodgkin 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Gastrointestinal Stromal Tumors 6Cholangiocarcinoma 6Triple Negative Breast Neoplasms 5Stomach Neoplasms 5Neoplasm Metastasis 5Leukemia, Lymphocytic, Chronic, B-Cell 5Thyroid Neoplasms 4Lymphoma, Mantle-Cell 4

Interventions

olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Expanded_access × Ovarian Diseases × Clear all
NCT03079687 2017-10-25

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

AstraZeneca

Approved for marketing
Gynecologic

Carcinoma, Ovarian Epithelial, Neoplasms, Ovarian Diseases, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡